Editas Medicine Inc (NAS:EDIT)
$ 1.199 -0.011 (-0.91%) Market Cap: 99.88 Mil Enterprise Value: -126.72 Mil PE Ratio: 0 PB Ratio: 0.57 GF Score: 46/100

Editas Medicine Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 02:00PM GMT
Release Date Price: $9.17 (+1.66%)
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Great. Well, thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

With that out of the way, we're very pleased to have Editas joining us this morning. Today from the company, we have Gilmore O'Neill, who is President and CEO; and Baisong Mei, who is Senior Vice President and Chief Medical Officer. Thank you both so much for being here today.

Questions & Answers

Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst

Maybe to start us off, just kind of a high-level question here. Back earlier this year, you announced plans to reprioritize the company's pipeline. Maybe just give us an update

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot